<DOC>
	<DOCNO>NCT02484690</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , efficacy RG7716 participant subfoveal CNV secondary AMD .</brief_summary>
	<brief_title>AVENUE : A Proof-of-Concept Study RG7716 Participants With Choroidal Neovascularization ( CNV ) Secondary Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adults least 50 year age Subfoveal CNV lesion type , secondary AMD Active CNV CNV due cause AMD Subretinal hemorrhage , fibrosis , atrophy involve either fovea 50 % total lesion area Cataract surgery within 3 month Baseline , previous intraocular surgery Major illness surgery within 1 month prior Screening Hemoglobin A1c 7.5 percent ( % ) Uncontrolled blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>